Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist
le Roux CW, Steen O, Lucas KJ, et al.
Diabetes Obes Metab. Pub. online 16 Jan 2025.
Leggi
Three-year follow-up after antiviral treatment in new-onset type 1 diabetes: results from the diabetes virus detection and intervention trial
Mynarek IM, Krogvold L, Mørk FB, et al.
Diabetes Care. 2025:dc242121.
Leggi
Hypertensive disorders of pregnancy and gestational diabetes mellitus and predicted risk of maternal cardiovascular disease 10-14 years after delivery: a prospective cohort
Venkatesh KK, Grobman WA, Wu J, et al.
Diabet Med. 2025:e15516.
Leggi
The Virtual DCCT: adding continuous glucose monitoring to a landmark clinical trial for prediction of microvascular complications
Kovatchev BP, Lobo B, Fabris C, et al.
Diabetes Technol Ther. Pub. online 8 Jan 2025.
Leggi
Genetic predisposition to low-density lipoprotein cholesterol and incident type 2 diabetes
Ravi A, Koyama S, Cho SMJ, et al.
JAMA Cardiol. Pub. online 15 Jan 2025.
Leggi
Association of changes in the type 2 diabetes and MASLD/related SLD status with risk of developing cardiovascular disease
Matsubayashi Y, Fujihara K, Khin L, et al.
Diabetes Obes Metab. Pub. online 15 Jan 2025.
Leggi
Calorie (energy) labelling for changing selection and consumption of food or alcohol
Clarke N, Pechey E, Shemilt I, et al.
Cochrane Database Syst Rev. 2025;1:CD014845.
Leggi
Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial
Butt JH, Jhund PS, Henderson AD, et al.
Lancet Diabetes Endocrinol. Pub. online 13 Jan 2025.
Leggi
Definition and diagnostic criteria of clinical obesity
Rubino F, Cummings DE, Eckel RH, et al.
Lancet Diabetes Endocrinol. Pub. online 14 Jan 2025.
Leggi
Sugar-sweetened or artificially sweetened beverage consumption, physical activity and risk of type 2 diabetes in US adults
Pacheco LS, Tobias DK, Haslam DE, et al.
Diabetologia. Pub. online 8 Jan 2025.
Leggi